PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy

ConditionLymphoma

Trial statusRecruiting

Trial phasePhase 3

Trial typeInterventional

Biological sexAll

Age18+

SponsorSherief Abd-Elsalam

About this trial

The study is a Comparative Clinical and Biochemical Study Evaluating the effect of Proton Pump I nhibitors versus histamine 2 Receptor antagonists as an adjuvant with chemotherapy in patients with Non-hodgkin Lymphoma.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

DLBCL Lymphoma subtype --No comorbid disease

Disqualifiers

Pregnancy

Peptic ulcer

Severe cardiac disease

Osteoporosis

Trial design

Design model

Parallel

Treatments tested in this trial

CHOP
Drug
CHOP only
CHOP Plus Lanzoprazole
Drug
CHOP plus Lanzoprazole 60 mg
CHOP Plus Famotidine
Drug
CHOP Plus Famotidine 40 mg

Treatment groups

60 Participants

are divided into 3 treatment groups

Group A: CHOPActive comparator 1 intervention

Group B: CHOP Plus LanzoprazoleActive comparator 1 intervention

Group C: CHOP Plus FamotidineActive comparator 1 intervention

Trial outcomes

Primary outcomes

Number of patients eith radiological and clinical improvement

Number of patients eith radiological and clinical improvement after cycles of chemotherapy

Time frame

6 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Sherief Abd-Elsalam

Lead sponsor

Tanta University

Sponsor institution

Source ClinicalTrials.gov

Apply now